Search
FDA's Streamlined Nonclinical Safety Guidance for Monoclonal Antibodies: What It Means for Regulatory Affairs Professionals in 2026
In December 2025, the US Food and Drug Administration (FDA) published draft guidance — "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies" (Docket FDA-2025-D-4634) — recommending that sponsors of monospecific monoclonal antibodies (mAbs) can reduce or eliminate long-duration animal toxicology studies, including in nonhuman primates (NHPs), where a robust weight-of-evidence (WoE) risk assessment supports doing so. It affects any company developing single-target mAb
4 days ago11 min read
eCTD 4.0 Explained: FDA, EMA and Japan Deadlines, Key Changes and What It Means for Regulatory Affairs Careers
**eCTD 4.0** is the next-generation global standard for electronic pharmaceutical regulatory submissions, replacing the document-centric **eCTD 3.2.2** format used since 2008. It affects regulatory affairs professionals, publishing specialists and every company submitting dossiers to the **FDA**, **EMA**, **PMDA** and other health authorities. The **FDA** has accepted eCTD 4.0 for new applications since **16 September 2024**; **Japan** targets a mandate by **April 2026**; and
Aug 1212 min read
FDA's August 2026 PDUFA Wave: Five Landmark Decisions Regulatory Affairs Professionals Need to Know
The FDA PDUFA dates for August 2026 mark one of the busiest single-month regulatory windows of the year, with five separate Prescription Drug User Fee Act (PDUFA) decisions due between 5 and 28 August. The decisions affect a new mRNA influenza vaccine, an oral multiple myeloma therapy, a single-tablet HIV regimen, a radiopharmaceutical for neuroendocrine tumours, and a first-in-class treatment for an ultra-rare bone disorder. Sponsors include Moderna, Bristol Myers Squibb, Gi
Aug 712 min read
FDA Approves Tregzi (Orca-T) for GvHD Prophylaxis
The US Food and Drug Administration (FDA) approved Tregzi (Orca-T) on 30 June 2026, making it the first regulatory T cell-based immunotherapy authorised to improve chronic graft-versus-host disease (cGvHD)-free survival in adults undergoing matched donor allogeneic haematopoietic stem cell transplantation (allo-HSCT) for haematological malignancies. Developed by Orca Biosystems, Inc. (Orca Bio), Tregzi combines purified haematopoietic stem and progenitor cells (HSPCs), regula
Jul 2812 min read
10 Clinical Trials to Watch in H2 2026: From Lung Cancer Immunotherapy to Personalised Cancer Vaccines — A Regulatory Affairs Briefing
The most closely watched clinical trials to watch in H2 2026 span lung cancer immunotherapy, personalised mRNA cancer vaccines, obesity drugs, rare neuromuscular disease and novel anticoagulants, according to industry tracking from BioPharma Dive. These trials affect oncologists, biotech investors, sponsors and regulatory affairs teams preparing dossiers across the FDA, EMA and MHRA. Readouts expected between July and December 2026 will shape marketing authorisation strategy,
Jul 1012 min read
Guiding Principles of Good AI Practice in Drug Development: What Every Regulatory Professional Needs to Know
In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published one of the most significant regulatory science documents in recent memory: Guiding Principles of Good AI Practice in Drug Development. For the first time, the world's two most influential regulatory authorities have aligned on a shared framework governing how artificial intelligence must be developed, validated, documented, and managed across the entire pharm
Jul 912 min read
FDA Approves Lumvoa (Veligrotug-vvze) for Thyroid Eye Disease — What Regulatory Affairs Professionals Need to Know
The US Food and Drug Administration (FDA) approved Lumvoa (veligrotug-vvze) on 26 June 2026, making it the first therapy indicated for both active and chronic thyroid eye disease (TED). Developed by Viridian Therapeutics, Lumvoa is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R), delivered as five intravenous infusions over 12 weeks — a shorter course than the existing standard of care. Approval was supported by the pivotal Phase 3 THRIVE and THRIVE-2
Jul 812 min read